cash position

28 articles
Investing.comInvesting.com··Dan Schmidt

Costco's $16B War Chest Fuels Special Dividend Speculation for 2026

Costco may distribute a special dividend in 2026 given its $16.2B cash position and 2.75-year distribution pattern, though 50x valuation and tariff risks present headwinds.
COSTBJstock valuationcash position
BenzingaBenzinga··Century Casinos, Inc.

Century Casinos Posts Record Q1 Revenue as Operating Profits Surge 65%

Century Casinos reports record Q1 revenue of $137.2M (+5% YoY) with operating earnings surging 65% to $11.8M, though net loss of $16.5M persists.
CNTYcash positionQ1 2026 earnings
BenzingaBenzinga··Prnewswire

Syra Health Reaches Profitability Milestone in Q1 2026 Amid Strong Margin Expansion

Syra Health reports first profitable quarter with $241K net income, 22% revenue growth to $2.3M, and 11-point gross margin expansion amid strong population health momentum.
SYRAcash positionprofitability
The Motley FoolThe Motley Fool··Motley Fool Transcribing

OraSure Charts Path to Profitability With Margin Expansion and FDA Pipeline

OraSure posts 4% Q1 revenue growth to $27.9M with gross margin expansion to 42.3%, maintaining $177M cash. Two FDA submissions expected midyear clearance with 2027 breakeven guidance.
OSURoperating lossescash position
The Motley FoolThe Motley Fool··Trevor Jennewine

Buffett's Successor Sends $397B Warning as Stock Market Valuations Hit 26-Year Peak

Berkshire Hathaway CEO Greg Abel signals market concerns amid record $397B cash position. S&P 500 CAPE ratio hits highest level since dot-com bubble.
BRK.ABRK.Bcash positionstock market valuation
Investing.comInvesting.com··Christine Short

Berkshire's Buffett Era Ends: Can New CEO Abel Navigate $370B Cash Pile?

Berkshire Hathaway transitions to new CEO Greg Abel as stock lags S&P 500 by 31 points, saddled with record $370-380B cash pile amid scarce investment opportunities.
BRK.ABRK.Bcash positionBerkshire Hathaway
The Motley FoolThe Motley Fool··Keith Noonan

GameStop's $9B War Chest Tempts Investors—But CEO Cohen Must Show His Hand First

GameStop has amassed $9 billion in cash, signaling major acquisition plans. Investors should wait for CEO Ryan Cohen to clarify targets before buying.
GMEGME.WSacquisitioncash position
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Paul Mueller Reports Q1 2026 Earnings Miss Amid Project Costs, But FY Outlook Brightens

Paul Mueller Q1 2026 net income fell 53% to $2.3M on $66.4M revenue due to project costs, but full-year earnings improved 6.3% to $32.1M with strong $235.6M backlog.
MUELproject delayscash position
The Motley FoolThe Motley Fool··Motley Fool Transcribing

Innospec Posts Mixed Q4 Results as Oilfield Services Stumble

Innospec's Performance Chemicals surged 23%, but Oilfield Services plummeted 40%. Adjusted net income hit $46.3M despite $155.6M pension charge.
IOSPmargin improvementcash position
GlobeNewswire Inc.GlobeNewswire Inc.··Carbios

Carbios Cuts Costs by €7M, Eyes Asian Expansion Amid Strategic Pivot

Carbios reduced operating expenses €7M in 2025, posted €34.3M net loss, and maintains €59M cash reserves while planning Longlaville project restart and Asia expansion.
PEPLRLCYcash positionAsia expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Carbios

Carbios Slashes Operating Losses by €7M as Biorecycling Firm Targets Asia Expansion

Carbios cuts operating losses by €7M in 2025, maintains €59.1M cash position, and pursues Asia expansion through Wankai licensing deal while resuming Longlaville industrial project.
PEPLRLCYcash positionAsia expansion
The Motley FoolThe Motley Fool··James Halley

CRISPR's $2B War Chest Powers Gene-Therapy Expansion as Casgevy Sales Accelerate

CRISPR Therapeutics holds $2B cash reserves funding gene-therapy expansion, while Casgevy sales accelerate to $116M in 2025.
CRSPbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Files 2025 Earnings as Cash Position Supports MASH Drug Development

Inventiva filed 2025 regulatory documents with €99.3M cash on hand, advancing lanifibranor Phase 3 trial for metabolic liver disease treatment.
IVAPhase 3 clinical trialfinancial results
BenzingaBenzinga··Lekha Gupta

Rocket Lab Stock Surges 5.47% on Completed $474M Offering and Analyst Upgrade

Rocket Lab stock jumped 5.47% Wednesday after completing a $474M equity offering and receiving a Citizens Bank upgrade to Market Outperform with an $85 price target.
RKLBXARARKQARKXanalyst upgradecash position
The Motley FoolThe Motley Fool··Jonathan Ponciano

C3.ai Stock Plunges 55% as CEO Offloads Holdings Amid $133M Quarterly Loss

C3.ai shares down 55% over one year following $133M quarterly loss; CEO insider sale adds to concerns despite $621.9M cash position.
AIstock declinecash position
The Motley FoolThe Motley Fool··Marc Guberti

Comfort Systems USA's AI Boom: Can $FIX Stock Turn $100K Into $1 Million?

$FIX stock surges 54% YTD on AI data center cooling demand, $12B backlog, and 41.7% sales growth. Can it deliver millionaire-level returns?
FIXAI infrastructurecash position
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Highlander Silver Merger Complete; Corani Drilling Launches With $100M Cash

Highlander Silver completes Bear Creek merger, reports $100M cash, begins drilling at world's largest permitted primary silver project in Peru.
HSLVcash positiongold mining
The Motley FoolThe Motley Fool··Keith Noonan

GameStop Defies Retail Decline as Cohen's Transformation Strategy Trumps Revenue Slump

GameStop Q4 revenue fell 14.1% to $1.1B, yet adjusted EPS surged 63% to $0.49. With $9B cash and strategic shift under Cohen, meme stock bet now hinges on acquisition strategy.
MSFTSONYNTDOYGMEGME.WSearnings growthcash position
The Motley FoolThe Motley Fool··Motley Fool Transcribing

IPM Swings to Positive EBITDA as Managed Services Growth Offsets Revenue Dip

Intelligent Protection Management reported Q4 2025 revenue of $6.1M with declining net losses and positive adjusted EBITDA, while completing strategic acquisitions and partnerships.
IPMacquisitiondata center
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Olema Oncology Advances Breast Cancer Pipeline, Secures $218.5M in Funding

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.
PFEOLMAPhase 3 trialsclinical development